Pulmonx Corporation (LUNG) Stock Analysis

Pulmonx (LUNG) Q3 2026 Earnings Call Transcript

Tue, October 27, 2026 at 11:43 PM UTC 3 min read

Pulmonx (LUNG) reported its Q3 2026 earnings, showcasing a significant increase in revenue driven by strong demand for its lung volume reduction technology. The company highlighted advancements in its product pipeline and expanding market presence, which could enhance its competitive position in the respiratory health sector. For investors, these developments signal potential for sustained growth and profitability, making LUNG an attractive option in the healthcare market.

Read full article →

Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?

Mon, August 3, 2026 at 4:00 PM UTC 4 min read

Pulmonx (LUNG) has been upgraded to a "Buy" rating by analysts, signaling increased confidence in the company's growth potential and market performance. This upgrade is significant for investors as it suggests a positive outlook for LUNG's stock, potentially leading to higher demand and price appreciation. Investors may view this as an opportunity to capitalize on the anticipated upward momentum in the company's valuation.

Read full article →